Articles related to HORMONE REPLACEMENT THERAPY (HRT)

ACP places estrogen-based therapy first in its pharmacologic pathway for menopausal vasomotor symptoms, with nonhormonal alternatives for contraindications or intolerance. Recommendation strength and evidence certainty vary, and long-term safety evidence remains limited.

A large Danish registry study found that current use of oral menopausal hormone therapy was associated with increased venous thromboembolism risk, while transdermal therapy was not generally associated with higher thrombotic rates across regimens, doses, or durations.

Reevaluation of major hormone therapy studies has prompted renewed discussion about menopause treatment in breast cancer survivors. Emerging interpretation of older trial data suggests treatment risks may vary by patient characteristics and hormone formulation rather than applying uniformly across all populations.

Menopausal hormone therapy users showed significantly higher bone mineral density at the spine and hip than non-users in a retrospective cohort of 387 postmenopausal women.

Hormone therapy status was associated with differences in diet, physical activity, and sleep guideline adherence in a cross-sectional analysis of more than 10,000 women.

A case of chemotherapy-induced menopause left unmanaged for six years prompted a physician’s pointed critique of survivorship care failures, highlighting the clinical and legal stakes of untreated premature ovarian insufficiency following gonadotoxic therapy.